Isomorphic Labs raises $5 billion in Series C funding
Greenoaks and Sequoia co-led the round, and the Alphabet-backed drug design company said it will use the money to move preclinical oncology and immunology programs toward the clinic.
. 2-minute read.

Isomorphic Labs announced Tuesday that it raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor and Alphabet continuing to back the company. The company has not publicly disclosed a drug candidate or reached the clinic.
BioSpace reported the round sets a record for the most money raised in a single biotech venture round, surpassing Altos Labs' $3 billion launch in 2022, and is more than twice Isomorphic's $2.1 billion Series B from May. HedgeCo reported that existing backers including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also took part, though Isomorphic did not reveal its valuation. Bloomberg had previously reported that the company was looking to raise money at a valuation near $50 billion.
The fresh capital will scale the company's IsoDDE drug design engine and fund translational and clinical development infrastructure, Isomorphic said. The company said it has seen encouraging preclinical data from its own oncology and immunology candidates as well as from partnered research. Its research collaborations include Eli Lilly, Novartis and Johnson & Johnson.
In a September demonstration, scientists gave an AI agent a molecular design brief that included a biological target and required drug properties. The agent's search ran for a period of two to four days. Scientists then made selected compounds and tested them, and one changed the target's activity in the laboratory, according to the company.
Isomorphic has also described advances on unfamiliar biology. In February, the company reported that its models scored more than double the accuracy of AlphaFold 3 on the most difficult class of a benchmark for protein–ligand structures, and it also recreated a previously unknown binding site on cereblon that had been found through experiments.
Isomorphic started working with Novartis in 2024 on three difficult targets, and in 2025 the deal grew to add up to three more programs. Its work with Lilly centers on finding small molecules against unnamed targets, while the Johnson & Johnson partnership covers several kinds of therapeutics. Teams review evidence together and decide which compounds to make and test next.
Hassabis said in a statement that the engine is generating molecules with "unprecedented precision and speed," and that the round lets the company accelerate "building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials". Isomorphic President Max Jaderberg said the company aims to "unlock some of the hardest problems in drug discovery".
Isomorphic has not publicly named a molecule, BioSpace reported. According to HedgeCo, the company said regulatory filings for its first oncology program are progressing and it expects further news in 2027. In the end, the value investors assigned will be tested by results from human trials, HedgeCo noted.
Sources: Deployed, BioSpace, HedgeCo.Net
Corrections. Report an error to corrections@clinicalobserver.com. Read our corrections policy.